Development of a biofilm inhibitor molecule against multidrug resistant Staphylococcus aureus associated with gestational urinary tract infections by P. Balamurugan et al.
ORIGINAL RESEARCH
published: 11 August 2015
doi: 10.3389/fmicb.2015.00832
Frontiers in Microbiology | www.frontiersin.org 1 August 2015 | Volume 6 | Article 832
Edited by:
Matthew P. McCusker,
University College Dublin, Ireland
Reviewed by:
Luis Cláudio Nascimento Da Silva,
University of Copenhague, Denmark
Henrietta Venter,
University of South Australia, Australia
*Correspondence:
S. Adline Princy,
Quorum Sensing Laboratory, Centre
for Research on Infectious Diseases,
School of Chemical and
Biotechnology, SASTRA University,
Thanjavur 613401, Tamil Nadu, India
adlineprinzy@biotech.sastra.edu
Specialty section:
This article was submitted to
Antimicrobials, Resistance and
Chemotherapy,
a section of the journal
Frontiers in Microbiology
Received: 07 May 2015
Accepted: 28 July 2015
Published: 11 August 2015
Citation:
Balamurugan P, Hema M, Kaur G,
Sridharan V, Prabu PC, Sumana MN
and Princy SA (2015) Development of
a biofilm inhibitor molecule against
multidrug resistant Staphylococcus
aureus associated with gestational
urinary tract infections.
Front. Microbiol. 6:832.
doi: 10.3389/fmicb.2015.00832
Development of a biofilm inhibitor
molecule against multidrug resistant
Staphylococcus aureus associated
with gestational urinary tract
infections
P. Balamurugan 1, M. Hema 1, Gurmeet Kaur 1, V. Sridharan 2, P. C. Prabu 3,
M. N. Sumana 4 and S. Adline Princy 1*
1Quorum Sensing Laboratory, Centre for Research on Infectious Diseases, School of Chemical and Biotechnology, SASTRA
University, Thanjavur, India, 2Department of Chemistry, Centre for Research on Infectious Diseases, School of Chemical and
Biotechnology, SASTRA University, Thanjavur, India, 3Central Animal Facility, SASTRA University, Thanjavur, India,
4Department of Microbiology, JSS Medical College and JSS University, Mysore, India
Urinary Tract Infection (UTI) is a globally widespread human infection caused by an
infestation of uropathogens. Eventhough, Escherichia coli is often quoted as being the
chief among them, Staphylococcus aureus involvement in UTI especially in gestational
UTI is often understated. Staphylococcal accessory regulator A (SarA) is a quorum
regulator of S. aureus that controls the expression of various virulence and biofilm
phenotypes. Since SarA had been a focussed target for antibiofilm agent development,
the study aims to develop a potential drug molecule targeting the SarA of S. aureus
to combat biofilm associated infections in which it is involved. In our previous studies,
we have reported the antibiofilm activity of SarA based biofilm inhibitor, (SarABI) with
a 50% minimum biofilm inhibitory concentration (MBIC50) value of 200µg/mL against
S. aureus associated with vascular graft infections and also the antibiofilm activity of
the root ethanolic extracts of Melia dubia against uropathogenic E. coli. In the present
study, in silico design of a hybrid molecule composed of a molecule screened from
M. dubia root ethanolic extracts and a modified SarA based inhibitor (SarABIM) was
undertaken. SarABIM is a modified form of SarABI where the fluorine groups are absent
in SarABIM. Chemical synthesis of the hybrid molecule, 4-(Benzylamino)cyclohexyl
2-hydroxycinnamate (henceforth referred to as UTI Quorum-Quencher, UTIQQ) was then
performed, followed by in vitro and in vivo validation. The MBIC and MBIC of UTIQQ50 90
were found to be 15 and 65µg/mL, respectively. Confocal laser scanning microscopy
(CLSM) images witnessed biofilm reduction and bacterial killing in either UTIQQ or in
combined use of antibiotic gentamicin and UTIQQ. Similar results were observed with
in vivo studies of experimental UTI in rat model. So, we propose that the drug UTIQQ
would be a promising candidate when used alone or, in combination with an antibiotic
for staphylococcal associated UTI.
Keywords: uropathogen, Staphylococcus aureus, quorum sensing, biofilm, Melia dubia, hybrid molecule,
multidrug resistance
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Introduction
Urinary Tract Infections (UTIs) are among the most common
infections that necessitate a hospital visit; some estimates
claim UTI to be the second most common infection after the
common cold, and being the primary cause of over eight million
annual hospital appointments (Schappert and Rechtsteiner,
2008). The infection can be asymptomatic where there is no
apparent indication of the infection, or can degenerate into a
symptomatic version, with the usual symptoms being frequent
and/or painful urination accompanied with abdominal pain and
cloudy or bloody rancid-smelling urine. Fever during UTI is
often indicative of pyelonephritis, a condition where the infection
has reached the kidneys and requiring immediate medical
attention. Kidney UTIs are deadly in the case where it effects
septicemia, leading to infection in the bloodstream, and can
cause systemic infection. Women are more prone to UTIs than
men. Several factors are responsible for this—shorter urinary
tract, proximity of the urethra to the anal opening, hormonal
imbalances and fluctuations leading to pH rise in urethra and
use of contraceptives and spermicides are among the prime
causes (Stamm and Raz, 1999). About 5% of pregnant women
develop UTI (Sharma et al., 2009) and they experience urine
retention and urinary reflux that leaves the urothelium vulnerable
to infection. The infection, untreated, leads to premature births,
morbidity, and mortality in pregnant women (Warren et al.,
1999). Gestational UTI is also identified to be the cause of 27%
of miscarriages and premature births in a study involving mice
(Kaul et al., 1999). Further, risks of pyelonephritis increase with
pregnancy. Problems concerning UTI during pregnancy include
the non-availability of first-line antibiotics like fluoroquinolones
and trimethoprim, primarily because of the side-effects to fetal
development (Jancel and Dudas, 2002; Lee et al., 2008).
An assortment of microorganisms act as perpetrators
of UTI and Escherichia coli is the primary organism to
cause more than 80% of UTI. Other organisms responsible
are Staphylococci, Klebsiella, Proteus mirabilis, Enterococcus,
Pseudomonas aeruginosa, and Serratia marcescens. Of the fungal
causatives, Candida sp. are most prominent to complicate UTIs
that involves Candida “yeast infections” and coagulase-positive
Staphylococci that may lead to septicemia ultimately. The role
of Staphylococcus aureus is often understated and there is an
increasing prevalence of S. aureus in UTI in recent years (Akortha
and Ibadin, 2008). In the earlier studies, S. aureus was found
to be the second most prevalent pathogen in UTI, and it is of
higher incidence in women (Onanuga and Awhowho, 2012). It
is known to cause 3–6% of UTIs, and up to 25% of UTIs in
some cases (Wasnik and Tumane, 2013). Adherence of bacteria
to the uroepithelial tissues is important for ascending infection,
and hence the formation of biofilm-like communities within
the urinary bladder complicates treatment. Also the multidrug
resistance (MDR) is associated with biofilm formation in several
bacteria, increases the inability of antibiotics to penetrate biofilms
playing a key role in such behavior. Most of the virulence
factors are expressed by the pathogens during an infection,
in tandem, coordinated by a signaling mechanism termed as
quorum sensing.
Quorum sensing in Staphylococci is usually mediated by two
pathways namely the staphylococcal accessory regulator (sar)
and accessory global regulator (agr) cascades. The agr pathway
is a more specific pathway that regulates quorum sensing
in the pathogen, involving the secretion of a signal peptide
extracellularly, and its recognition leading to the expression of
virulence factors. The sarA locus is more of a global control
cascade, controlling the manifestation of many virulence genes,
with its mutation known to affect 120 genes, with 76 of them
positively regulated and 44 genes negatively regulated (Dunman
et al., 2001). The SarA family of proteins includes SarR, SarS,
SarT, SarU, SarV, and MgrA, all of which share sequence
homology (Cheung et al., 2004; Manna et al., 2004). Mutation
of sarA effects out reduced biofilm production capabilities,
regardless of the status of agr cascade expression (Beenken
et al., 2010). Moreover, the role of SarA in agr-independent
expression of several other virulence genes like activation of fnbA
(fibronection binding protein A) and bap (biofilm associated
proteins) had been explained in the previous studies (Trotonda
et al., 2005; Roberts et al., 2006). In our previous study, we have
experimentally proved that targeting SarA inhibition would be an
effective way of inhibiting the biofilm (Arya et al., 2015).
Melia dubia which is called as malai vembu indigenously is
a plant of many wonderful medicinal properties. Belonging to
the Meliaceae family of plants it is found at an elevation of 600–
1800m in the South Indian Ghats, India. Its leaves, barks and
fruits have insect repellant properties. The leaf of this tree has
essential oils constituted by monoterpene camphene, α-pinene,
β-pinene, and sabinene, are is rich in antimicrobial, antiviral, and
antineoplastic activity (Nagalakshmi et al., 2003). There has also
been successful preventive therapy using infusions ofM. dubia in
Tamil Nadu, India against dengue virus. The methanolic fraction
of this plant has anti-larval properties (Koul et al., 2000).
The present study involves the screening, synthesis and
validation of a potent compound against SarA of S. aureus
associated with gestational urinary tract infections, in light of
our previous studies that showed potent antibiofilm activity in
root ethanolic extract of M. dubia against uropathogenic E.
coli (Vinothkannan et al., 2013; Adline Princy et al., 2014) and
antibiofilm activity of SarABI against S. aureus associated with
vascular graft infections (Arya et al., 2015). In brief, the proposed
inhibitor, UTIQQ against SarA protein was computationally
validated to have a high affinity toward the target and it was
synthesized by a two step process, i.e., reductive amination and
steglich esterification for further in vitro and in vivo validation.
Materials and Methods
Strains
Urine samples (N = 100) were collected at random from the
pregnant women during their pre-natal visit at Mother and Child
Care Maternity Hospital, Thanjavur between May 2013 and July
2013 and the status of infection and pyuria was analyzed by
centrifugation at 6000 rpm, 5min, followed count of pathogens
by the colony count. Pathogenic strains from the confirmed cases
causing the urinary tract infections were isolated. The strains
were then screened for MDR against a variety of antibiotics used
Frontiers in Microbiology | www.frontiersin.org 2 August 2015 | Volume 6 | Article 832
Balamurugan et al. Biofilm inhibitor molecule against uropathogenic MRSA
for conventional UTI treatment. The isolated strains (Table 1)
were cultured in enriched tryptic soy broth and used for the
subsequent study.
Extraction of Plant Material and Biofilm Assay
TheM. dubia root samples collected fromThanjavur, Tamil Nadu
were subjected to the process of extraction at room temperature
(30 ± 1◦C), through cold percolation methods using different
solvents (water, hexane, petroleum ether, ethanol, and methanol)
in the proportion of 100 g powdered root in 900mL solvent.
The mixture was regularly stirred for 72 h after which the
supernatant was recovered by filtration and the solvent in the
supernatant was evaporated in a rotary evaporator. The crude
extract was lyophilized and stored at −80◦C (Ravichandiran
et al., 2012). The antibiofilm efficacy of M. dubia extracts of
different concentrations was observed using a modified crystal
violet method as described (O’Toole and Kolter, 1998). The
extracts were dissolved in 1X phosphate buffer saline (1X PBS)
for the assay. Since the root ethanolic extracts displayed good
antibiofilm activity against S. aureus, it was taken for the further
studies.
Gas Chromatography Mass Spectrometry
(GC-MS)
GC-MS analysis was carried out for the root ethanolic extract of
M. dubia using a PerkinElmer Clarus 500 GC-MS system. The
program was set at a temperature of 50◦C for a duration of 1min
and raised at 10◦C/min to 150◦C (1min hold), at 8◦C/min to
250◦C (1min hold), at 15◦C/min to 300◦C (3min hold). Helium
(1mL/min) was used as carrier gas. The injector temperature
was maintained at 280◦C and the mass range was 40–450 amu.
One microliter of sample dissolved in ethanol was injected into
the system. The identification of the compounds was made by
comparing their spectra with the National Institute of Standard
and Technology (NIST) spectral library.
Computational Studies
The compounds reported by GC-MS were drawn using ACD
Chemsketch™. The energy minimized 3D ligand conformers
were prepared using Schrödinger™ LigPrep software. Glide
module of Schrödinger was used for the molecular docking
analysis. OPLS-2005 force field was utilized to optimize the
TABLE 1 | Strains used in this study.
Strain Identifier References
Staphylococcus aureus reference
ATCC
ATCC25923 Levy et al., 2003
Staphylococcus aureus sarA mutant
(1sarA::Tn917LTV1)
ALC637 Wolz et al., 2000
Escherichia coli clinical isolate EC67a Princy et al., 2014
Staphylococcus aureus clinical isolate
(MRSA)
SA13a Princy et al., 2014
Pseudomonas aeruginosa clinical
isolate
PA07c Princy et al., 2014
Klebsiella pneumonia clinical isolate KP32b Princy et al., 2014
Enterococcus faecalis clinical isolate EF32e Princy et al., 2014
geometry and for minimization. SarA protein structure 2FNP
(Liu et al., 2006), was prepared and the receptor grid was
generated encompassing the whole protein, with the centroid
of the protein fixed with a grid size of 20 Å. The compounds
were also analyzed for their suitability for the use as a drug
molecule, based the Lipinski’s Rule of Five. Also, the ADMET
(Absorption, Distribution, Metabolism, Excretion, Toxicity)
parameters predicted by the Topkat module of Accelrys™
Discovery and Quikprop module of Schrödinger™ Suite were
taken into consideration for the efficient screen of various
compounds with drug-likeness properties.
The candidate molecule o-coumaric acid, as identified by
the in silico techniques had a carboxylate functional group,
and had affinity to bind to R84, more than DER box (88,
89, and 90). Our earlier study had established the molecule
4-(2,4-difluorobenzylamino)cyclohexanol, SarABI which bound
to E89 and R90 of SarA (Arya and Princy, 2013; Arya et al.,
2015). Since, the acid group of the candidate molecule identified
was undesirable, an ester linkage between the acid group
and the alcohol group of SarABI was proposed to have a
hybrid molecule and analyzed by in silico. Molecular docking
predicted that absence of fluorine groups in the hybrid molecule
had better binding affinity to SarA and hence a modified
SarABI (SarABIM) i.e., without fluorine atoms and o-coumaric
acid was considered for the chemical synthesis of a hybrid
molecule.
Chemical Synthesis of Hybrid Molecule, UTIQQ
The synthesis is comprised of two parts, reductive amination
and esterification (Figure 1). An equimolar mixture of cis 4-
aminocyclohexanol and benzaldehyde was refluxed in methanol
for 3 h at 70◦C along with 4 Å molecular sieves. The
mixture was cooled using an ice-water bath, and sodium
borohydride (l equiv.) was added in small portions. The
reaction was then stirred at room temperature overnight.
Reaction was quenched by adding cold water and extracted with
dichloromethane. The organic layer was washed with NaOH
solution, dried over anhydrous sodium sulfate solution and
concentrated to obtain the pure 4-(Benzyl amino)cyclohexanol
(SarABIM). 1H-NMR was used to confirm the synthesized
compounds.
This was followed by Steglich esterification (Neises and
Steglich, 1978). To a solution of SarABIM (0.2mmol),
DMAP (4-Dimethylaminopyridine) (0.2 equiv), and cis
o-coumaric acid/2-Hydroxycinnamic acid (1.2 equiv.) in
anhydrous dichloromethane (8mL), was added DCC (N,N′-
Dicyclohexylcarbodiimide) (1.2 equiv.) at 0◦C. The mixture was
stirred at room temperature until completion of the reaction.
The reaction mixture was filtered, and the residue was washed
with dichloromethane (2 × 10 mL). The solution was washed
with 5% HCl (3× 30 mL), saturated sodium bicarbonate (3× 30
mL) and saturated NaCl (3 × 30 mL), respectively. The organic
layer was then dried using sodium sulfate (anhydrous) and
vacuum dried. The residue containing the hybrid molecule,
4-(Benzylamino)cyclohexyl 2-hydroxycinnamate (henceforth
referred to as UTI quorum-quencher, UTIQQ) was used for
further assays.
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FIGURE 1 | Synthesis scheme for hybrid molecule, UTIQQ. The
compound, 4-(Benzylamino)cyclohexyl 2-hydroxycinnamate (UTIQQ) was
synthesized in two steps. The first step was reductive amination of
Benzaldehyde and 4-aminocyclohexanol. The second step was
esterification of 4-(Benzylamino)cyclohexanol and 2-hydroxycinnamic
acid/o-coumaric acid.
Determination of Minimum Biofilm Inhibitory
Concentration (MBIC)
Briefly, 100µl inoculum of S. aureus ATCC 25923 was plated
onto polystyrene microtiter plates in the proportion 1:200 (v/v)
from an overnight culture. Culturing was done in artificial urine
media (Brooks and Keevil, 1997). Varying concentrations of
UTIQQ ranging from 1 to 100µg/mL were added, in triplicates.
After 24 h, the planktonic cells were removed. PBS wash was done
thrice and the cells were fixed using 100µL of 99% methanol.
Then 150µL of 0.2% crystal violet was used for 20min to stain
the biofilm cells. Excess stains were removed by washing under
slow-flowing cold tap water and the plates were air dried. Again,
33% acetic acid was used to elute the bound crystal violet and
the optical reading was read in an ELISA plate reader (BioRad
i-Mark, Japan) at 595 nm (Stepanovic et al., 2000). The lowest
concentration of the compound that inhibits the biofilm by 50%
compared to untreated culture control is the minimum biofilm
inhibitory concentration (MBIC50) and that by 90% is MBIC90.
Determination of Minimum Inhibitory
Concentration (MIC) and Minimum Bactericidal
Concentration (MBC)
The minimum inhibitory concentration of a compound is
the lowest concentration that retards the visible growth of
the microorganism, and is a measure of the cell growth
parameters. The minimum bactericidal concentration is the
lowest concentration of the compound that causes cell viability
loss of 99.9%, i.e., only 1 in 1000 cell survives at MBC of a
compound. The cell density was measured at 600 nm before the
crystal violet biofilm assay to find the effect of the compound
on growth. Further the cells were plated after appropriate serial
dilutions of upto 108 X fold, in triplicates, onto the Cation-
Adjusted Muller-Hinton Agar (CAMHA) plates. The observed
count of the colony forming units per mL of broth (CFU/mL)
provides a measure of the survival of the cells. Untreated group
was taken as negative control. The experiments for in vitro drug
response were done twice independently.
Hydrophobicity Assay
18 h old culture (under UTIQQ treatment) in artificial urine
media was centrifuged. Mixed cultures of uropathogens were
grown in equi-volume ratios. Pellets obtained were washed in
PBS and resuspended to an OD550nm = 0.8 (A0). Three
milliliter of this suspension was mixed with 400µl of p-xylene,
equilibrated in a water bath at 25◦C for 10min and vortexed.
The lower aqueous phase optical density was measured at
550 nm (A1) (Basson et al., 2008). Measure of hydrophobicity
as percentage of adherence to xylene was calculated using
the formula given, and then standardized using the untreated
control.
%Hydrophobicity =
(A0 − A1)
A0
× 100
Confocal Laser Scanning Microscopy (CLSM)
Imaging
Biofilm of mixed bacterial population was developed onto
glass cover-slips in a six-well cell culture plate, under various
Frontiers in Microbiology | www.frontiersin.org 4 August 2015 | Volume 6 | Article 832
Balamurugan et al. Biofilm inhibitor molecule against uropathogenic MRSA
conditions of treatment using SarABIM, o-coumaric acid, hybrid
molecule UTIQQ and antibiotic gentamicin. This was performed
to assess qualitatively the effects of the UTIQQ on the biofilm of
the mixed population. After the biofilms were grown for 24 h,
the suspension was aspirated and removed carefully. The biofilm
was rinsed delicately in 0.9% NaCl solution. Stock solutions of
the fluorescein isothiocyanate (5mg/mL) and ethidium bromide
(1.25mg/mL) were prepared beforehand. Five microliter each of
the dyes were mixed with 1mL of cold 0.9% NaCl solution to
obtain a working solution. The biofilm was stained with 5µL of
the working solution of the dyes for 10min, and then the excess
dye was removed by washing with 0.9% NaCl. The cover-slip
was then dried for 2min in an ambient temperature and then
fixed using 50µL of toluene. Confocal imaging was performed
using Olympus Confocal Laser Scanning Microscope to obtain
the live/dead imaging (Netuschil et al., 1989). MIC of gentamicin
at 2µg/mL concentration was used along with the UTIQQ to
understand the combinatorial effects.
Cell Culture Studies
Hep-G2 cells were seeded in 48 well plate at a seeding density of
15,000 cells/well. The cells were checked for its confluence, once
it has attained 70% of confluence, the MBIC50 (15µg/mL) and
MBIC90(65µg/mL) concentrations of the synthesized UTIQQ
was added. After 24 h of incubation, the supernatant was used
for Lactate Dehydrogenase (LDH) assay. The remaining culture
medium was analyzed for cell viablity using MTT assay.
Lactate Dehydrogenase (LDH) Assay
Cytotoxicity of UTIQQ in its different concentrations was
determined by lactate dehydrogenase (LDH) assay. The assay
determines the release of cytoplasmic lactate dehydrogenase into
the cytosol due to the leakage of the damaged cells. After 24 h of
incubation 50µL of culture medium was collected and incubated
with the reaction mixture consisting of NAD+ (50µL), lactate
(50µL), and phosphate buffer (0.2 M) pH 7.4. The absorbance
was measured at 340 nm.
MTT Assay
The effect UTIQQ toward Hep-G2 cells was tested using two
concentrations, MBIC50 and MBIC90. The MTT cell viability
assay was followed (Zakaria et al., 2009). In brief, sub-confluent
HEp-G2 cells were added in the microtitre plate wells along
with DMEM medium. After adherence was established in the
plates (post 24 h incubation in CO2 incubator), UTIQQ was added
at an appropriate concentration to the wells, followed by 24 h
incubation and addition of MTT i.e., (3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) followed an incubation of
3 h with readings were recorded at every 1 h interval. 200µL of
isopropanol was added to the wells and OD was taken at 570 nm.
In vivo Studies
Induction of Experimental UTI in Pregnant Mice
by Bladder Catheterization
Institutional Animal Ethical Committee (IAEC) approval was
obtained to conduct the efficacy studies of UTIQQ and
antibiotics in experimentally disease induced animal models
(IAEC No: 222/SASTRA/IAEC/RPP). Groups of pregnant wistar
rats (Rattus norvegicus), three rats per group were infected with
uropathogenic S. aureus on day 7 of pregnancy (32% gestation)
by urethral catheterization. Briefly, animals were anesthetized
with thiopentone thiosol (40mg/kg) injection. The bacterial
inoculum (0.1mL of a suspension with an optical density at
600 nm of 0.5) was instilled into the urinary bladder through
a soft polyethylene catheter adapted to a needle on a syringe.
The control groups received sterile PBS. The rats were placed
in individual cages and allowed for free access to food and
drink under a 12-h day-night cycle. On the subsequent day,
the treatment groups were administered with gentamicin (low
dose, 8mg/kg and high dose, 50mg/kg) and the hybrid molecule
UTIQQ (low dose, 16mg/kg and high dose, 64mg/kg). The
animals were monitored daily for symptoms like preterm labor,
bleeding or any other sickness. Preterm is defined as any delivery
occurring on or before day 20 (90% gestation) of gestation (Kaul
et al., 1999). The survival of the pups delivered by these rats,
either term or preterm, was monitored and subsequent body
weights of those pups were also taken.
Quantitative Tissue Culture
Quantitative tissue culture was performed in a group of infected
rats before completing the delivery and sacrificed on day 17 (77%
gestation). Kidney was collected from each rat and homogenized
separately in 2.0mL of sterile PBS. After appropriate dilution,
samples were plated on mannitol salt agar (Himedia, Mumbai),
for selective isolation of uropathogenic S. aureus. The bacterial
counts were reported as CFU per gram of the tissues.
Histological Analysis of Tissues
Kidney samples collected for the histological analysis were fixed
overnight in formalin, embedded in paraffin, sectioned for the
immunohistochemical analysis and stained with hematoxylin
and eosin. Inflammation grades of 0 to 5 were assigned based
on the severity of infection as follows: 0, absent; 1, minimal; 2,
mild; 3, moderate; 4, marked; and 5, severe. The overall score
for the histopathological grading of pyelonephritis was based on
the pelvic, interstitial, and tubular involvement. All the tissue
samples were coded and read blind by the observer.
Statistical Analysis
Statistical analysis was carried out using GraphPad prism
software version 6.05 (GraphPad Software Inc., SanDiego, CA).
One-Way ANOVA followed by multiple comparisons using
Tukey’s test was used to test the significance. The minimum level
of significance was set at P ≤ 0.05. All the assays were conducted
in triplicates and the values were expressed as mean± SD.
Results
Extraction of Plant Material and Biofilm Assay
The efficacy of different solvent root extracts of M. dubia
in suppressing the traits responsible for the establishment of
microbial biofilm in ATCC 25923 reference strain of S. aureus
was tested. Ethanolic extract of the root served to be the best
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among all the solvent extracts as a biofilm inhibitor. Biofilm
formation was retarded by nearly 50% in the presence of
40µg/mL concentration of the root ethanolic extract (Figure 2).
Gas Chromatography Mass Spectrometry
(GC-MS) and Computational Studies
The gas chromatography mass spectroscopy (GC-MS) analysis
revealed the ingredients of root ethanolic extracts of M. dubia
(Table S1). The various components were analysed by in silico
docking simulation that predicts the binding affinity to the SarA
protein. The ligands were drawn using Chemsketch software and
used consequently for the computational studies. The 40 ligands
from the root ethanolic extract of M. dubia were pitted against
one another, in a bid to successfully unravel the best molecule
to proceed with. The top-hit molecules were identified with the
drug-likeness properties using the molecular docking software,
Schrödinger Suite (Table 2).
The interaction patterns of SarABI, o-coumaric acid and
SarABIM to SarA protein was shown in Figure 3. O-coumaric
acid has a carboxylate functional group, and showed higher
affinity to interact with the key residues, R84, more than DER box
FIGURE 2 | Determination of S. aureus ATCC 25923 biofilm formation
at different time intervals in response to crude root ethanolic extract of
M. dubia by crystal violet method. S. aureus ATCC 25923 was cultured in
tryptic soy broth with different solvent extracts of M. dubia in triplicates and
biofilm was quantified at different time intervals by crystal violet method.
Concentration at which 50% inhibition observed at all time intervals i.e.,
40µg/mL of root ethanolic extract is shown in the figure.
(88, 89, and 90). SarABI bound to E89 and R90 of SarA whereas
the SarABIM bound to D88 and E89 with a lesser glide score. The
binding pose of UTIQQ to SarA sites, represented by H-bonds at
R84 and Q64, and interaction diagram was shown in Figure 4.
Molecular docking predicted the absence of fluorine groups in
the hybrid molecule, UTIQQ that had a better binding affinity to
SarA. ADMET predictions revealed that UTIQQ would have oral
absorptivity of 100% and that the LD50 in rats would be 3 g/kg.
Chemical Synthesis and In vitro Validation of
UTIQQ
Chemical synthesis of UTIQQ was performed as described before.
Yield obtained in reductive amination step was 74% and in
esterification step was 58%. The products obtained as a yellow-
greenish mixture in the esterification step of reactions was
used for the subsequent assays. Minimum biofilm inhibitory
concentration of UTIQQ as determined by crystal violet biofilm
assay was 15µg/mL for 50% inhibition (MBIC50) and 65µg/mL
for 90% inhibition (MBIC90) (Figure 5). This was established
by fitting the data obtained on a log (inhibitor) vs. drug dose
response curve. Growth was reduced to 50% compared to
control at around 46µg/mL concentration of the drug molecule
(Figure 6). It was also observed that the survival of bacteria was
not much hampered in the range of concentrations tested (1–
100µg/mL) and MBC was greater than 100µg/mL (Figure 7).
This assay was performed by using the CAMHA plates in
triplicates, after appropriate serial dilutions.
It was also observed when UTIQQ was used in a co-culture of
uropathogens inclusive of S. aureus, biofilm reduced significantly
in 24 h and reduction was comparable with that of biofilm
induced by sarAmutant strain S. aureusALC637 (Figure 8). Also
there was no significant difference in the biofilm formation in
the sarA mutant strain (ALC637) when treated with the drug
(Figure S2).
Hydrophobicity Assay
It was found that in comparison with the untreated control,
hydrophobicity was reduced by more than 50% in the case of
the S. aureus clinical isolate monoculture (Figure 9A), or by 30–
35% in the case of the equivolume co-culture of uropathogens
(Figure 9B).
TABLE 2 | List of top 10 ligands based of docking G-score with interaction sites and logP-values.
S. No. Name of ligand Glide docking score Predicted interaction sites logP Molecular weight (Da)
1 Sucrose −6.751 K82, H87, R84, E89 −3.76 342.29
2 Vanillin lactoside −5.912 K82, R84, D88 −2.29 476.28
3 Ethyl d-glucopyranoside −5.624 Q64, R84, R90 −2.16 208.21
4 6-Deoxy L-galactose −5.256 Q64, R84, R90 −2.04 164.16
5 2-hydroxycinnamic acid/o-coumaric acid −4.785 Q64, R84, R90 +2.43 164.16
6 Cyclohexane carboxylic acid, 3-acetyloxyl −4.441 R90 +0.92 186.20
7 D-mannose −4.363 Q64, R84, R90 −3.17 180.16
8 1,6 Anhydro D-glucopyranose (levoglycan) −4.284 K82, R84, D88 −0.04 162.14
9 Benzenepropanol, 4-hydroxyl methyl −3.761 K54, Q64, R90 +1.49 166.25
10 Dianhydromannitol −3.642 Q64, R84, R90 −0.25 146.14
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FIGURE 3 | Interaction patterns of SarABI (A), o-coumaric acid
(B), and SarABIM (C) to SarA protein using Schrödinger
software. o-coumaric acid has a carboxylate functional group, and
had affinity to bind to R84, more than DER box (88, 89, and 90).
SarABI bound to E89 and R90 of SarA whereas SarABIM bound to
D88 and E89.
FIGURE 4 | Molecular docking of UTIQQ to SarA protein using Schrödinger software. (A) Binding pose of UTIQQ to SarA sites, represented by H-bonds at
R84 and Q64, (B) Interaction diagram also reveals the pi-cation interaction at R84.
Confocal Laser Scanning Microscopy
CLSM images of biofilm inhibition caused by the drug treatment
were taken as visual confirmation of the drug action (Figure 10).
The fixed biofilms were stained using FITC dye which fluoresces
green on attachment to the peptides on the surface of healthy
cells constituting the biofilm, while the stain EtBr intercalates
with the extracellular DNA formed as a result of the lysis
of cells and fluoresces red. Untreated cells were taken as the
negative control to further visualize the healthy biofilm. Drug
treatments with SarABIM, o-coumaric acid and UTIQQ showed
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FIGURE 5 | Effects of varying concentrations of UTIQQ on biofilm of
multidrug resistant S. aureus clinical isolate by crystal violet method.
S. aureus clinical isolate (SA13a) was cultured in artificial urine media exposed
with varying concentrations of UTIQQ ranging from 1 to 100µg/mL in
triplicates and biofilm was quantified at 595 nm after 24 h by crystal violet
method. X-axis represents increasing log concentration of the drug and Y-axis
represents the percentage of remaining biofilm compared to the untreated
culture control i.e., 100% biofilm. The 50% biofilm inhibition (MBIC50) and 90%
biofilm inhibition (MBIC90) of UTI
QQ are 15 and 65µg/mL, respectively.
FIGURE 6 | Effects of varying concentrations of UTIQQ on growth of
multidrug resistant S. aureus clinical isolate. S. aureus clinical isolate
(SA13a) was cultured in artificial urine media exposed with varying
concentrations of UTIQQ ranging from 1 to 100µg/mL in triplicates and growth
was measured at 600 nm after 24 h. X-axis represents increasing log
concentration of the drug and Y-axis represents the percentage of growth
compared to the untreated culture control i.e., 100% growth. Growth was
reduced to 50% compared to control at around 46µg/mL concentration of the
drug molecule.
disruption of biofilm, but not much of cell inhibition. Treatment
with gentamicin showed cell growth inhibition. When used in
combination with UTIQQ, the activity of gentamicin had been
confirmed to increase significantly with an increased levels of
dead cells in the biofilm.
Cell Culture Studies
Cell culture studies yielded the LDH value and the MTT assay
values required for determining the cytotoxicity of the drug.
The LDH concentration reflects the amount of the lysed cells in
the medium as it infers the cytotoxicity of the drug. The LDH
concentration was observed (Table S2) to be less in drug treated
cases when compared to the control as it strongly suggests that
the drug has a minimum or no cytotoxic effect.
FIGURE 7 | Effects of varying concentrations of UTIQQ on survival of
multidrug resistant S. aureus clinical isolate. S. aureus clinical isolate
(SA13a) treated with varying concentrations of UTIQQ ranging from 1 to
100µg/mL were plated onto Cation-Adjusted Muller-Hinton Agar (CAMHA)
plates. The grown colonies were counted to find the CFU/mL. Survival of
bacteria was not much hampered in the range of concentrations tested
(1–100µg/mL) and MBC was greater than 100µg/mL.
FIGURE 8 | Effect of UTIQQ on biofilm inhibition in co-culture
experiments by crystal violet method. S. aureus clinical isolate (SA13a)
was co-cultured with other uropathogens [clinical isolates such as E. coli
(EC67a), P. aeruginosa (PA07c), K. pneumonia (KP32b), and E. faecalis
(EF32e)] and exposed to MBIC50 (15µg/mL) as well as MBIC90 (65µg/mL) of
UTIQQ. Percentage biofilm inhibition was calculated with that of the untreated
co-culture biofilms. sarA mutant strain ALC637 (1sarA::Tn917LTV1) untreated
with UTIQQ was used for comparison of biofilm inhibition by the UTIQQ treated
co-cultures. Significant biofilm inhibition was observed in the co-cultures
treated with UTIQQ and was comparable to the biofilm of sarA mutant.
The Hep-G2 cell viability was also tested using MTT assay
which showed the drug, UTIQQ does not affect the viability of
the cells (Table S3) complementing the favorable characteristics
of the drug. This data significantly provides an insight that the
compound neither affects the viability nor toxic to the Hep-G2
cells to have drug-likeness effect.
In vivo Studies
In vivo studies of gestational UTI in pregnant rats showed
no preterm labor symptoms or preterm delivery of pups
and the percentage mortality observed was nil (Table S4).
Also, the difference of mean body weight of the pups
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FIGURE 9 | Hydrophobicity of bacterial cells treated with UTIQQ.
(A) Percentage adherence of multidrug resistant S. aureus clinical isolate
(SA13a) to xylene. (B) Percentage adherence of co-cultures of uropathogens
[clinical isolates such as E. coli (EC67a), S. aureus (SA13a), P. aeruginosa
(PA07c), K. pneumonia (KP32b) and E. faecalis (EF32e)] to xylene. UTIQQ
was administered at a concentration of 15µg/mL (MBIC50)and 65µg/mL
(MBIC90) to bacterial cultures and the treated cultures were exposed to
xylene. UTIQQ untreated bacterial cultures exposed to xylene were kept as
control. The difference was statistically tested to check the significance by
Multiple comparisons using Tukey’s test; Statistical significance *p < 0.05,
**p < 0.01, ***p < 0.001. Decreased hydrophobicity was observed in the
drug treated cultures.
FIGURE 10 | Live/dead staining observed using confocal laser
scanning microscopy. Biofilm of the mixed bacterial population
was developed onto glass cover-slips under various conditions of
treatment using SarABIM, o-coumaric acid, hybrid drug UTIQQ and
antibiotic gentamicin. (A) Control with no drug treatment, (B)
SarABIM treatment at MBIC50−(40µg/mL), (C) o-coumaric acid
treatment at MBIC50 (5µg/mL), (D) hybrid drug UTI
QQ treatment
at MBIC50 (15µg/mL), (E) Gentamicin treatment at MIC (2µg/mL),
(F) Synergetic effects of Gentamicin (2µg/mL), and UTIQQ
(15µg/mL).
between the control, diseased and the treated groups were
not significant (Figure S1). Table 3 shows the viable count
of bacteria recovered from tissue the homogenates of kidney.
Kidney sections of the control rats appeared histologically normal
with no significant pathological changes. Kidney sections of
rats inoculated with S. aureus had moderate hyperplasia of
the urothelium and chronic inflammation of moderate degree
in the renal pelvis characterized predominantly by varying
degrees of lympho-plasmacytic/polymorphonuclear infiltrates.
The transitional epithelium appeared hyperplastic with the
presence of a linear thickening of the lining epithelium with
lack of no prominent outward or inward growth. In case
of Gentamicin (LD) treated groups, a mild reduction in the
degree of inflammation was noted and at high dose levels of
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TABLE 3 | Viable count of bacteria recovered from tissue homogenates of
kidney.
Group S. aureus Log CFU/g ± SD
kidney
Control Nil
Diseased 5.9 ± 0.3
Gentamicin (LD) 6.0 ± 0.1
Gentamicin (HD) 2.0 ± 3.5
UTIQQ (LD) 5.9 ± 0.3
UTIQQ (HD) 3.9 ± 3.4
Gentamicin and UTIQQ (LD) 1.9 ± 3.2
Gentamicin and UTIQQ (HD) 1.9 ± 3.3
Gentamicin (LD, 8mg/kg and HD, 50mg/kg); Hybrid molecule UTIQQ (LD, 16mg/kg and
HD, 64mg/kg).
Gentamicin a moderate decrease in the degree of inflammation
was observed. Treatment with UTIQQ at both low and high dose
levels caused a mild to moderate reduction in the degree of
chronic inflammation associated with the urothelium. Combined
treatment of low dose of Gentamicin and UTIQQ resulted in
a mild to moderate reduction in the degree of inflammation,
whereas the high dose levels had marked a reduction in the
degree of inflammation present with few tubules of minimal
dilatation/degeneration (Figures 11, 12).
Discussion
The threat of MDR appears when a bacterial strain becomes non-
responsive to a wide range of antimicrobial concoctions. It is
an ever-escalating threat to public healthcare, necessitating the
need for the discovery of newer and more potent antibiotics. It
is even speculated that with the existing rate of spread of MDR,
antibiotics could become obsolete and ineffective. S. aureus is
one such classical notorious example of MDR pathogen, and
it defies attempts of microbial control, in a pattern observed
worldwide (Onanuga et al., 2005). Several infections, including
that of the urinary tract, can be caused by methicillin-resistant
S. aureus (MRSA), which is encountered at alarming rates, and
this eventually limits the choice of etiological control agents
employed to combat infections (Araki et al., 2002; Manikandan
et al., 2011). Also, it is an opportunistic pathogen and is known
to exhibit immuno-evasive strategies (Kuehnert et al., 2006).
Quorum sensing inhibitory approach is a promising alternative
to antibiotics which exerts least selective pressure that will
possibly prohibit the bacterial strains from attaining resistance
(Njoroge and Sperandio, 2009; Defoirdt et al., 2011). In the
present investigation, we have developed and evaluated a biofilm
inhibitor molecule against multidrug resistant S. aureus by
in vitro and in vivo studies.
In our previous studies, we have shown that the root ethanolic
extracts ofM. dubia displayed better antibiofilm activities against
S. aureus ATCC 25923 (Vinothkannan et al., 2013; Adline
Princy et al., 2014). In our another study, we have reported the
antibiofilm activity of SarABI against S. aureus associated with
vascular graft infections (Arya et al., 2015). In the present study
FIGURE 11 | Histological analyses of kidney tissue sections. (A) Kidney
sections of the control group of rat showing normal transitional
epithelium–urothelium (arrow) with no significant pathological changes. (B)
Kidney section of diseased rat inoculated with S. aureus revealing moderate
hyperplasia of the urothelium (arrow) and abundant lympho-plasmacytic
infiltration (LP). (C) Kidney section of rat inoculated with S. aureus and treated
with Gentamicin (LD) having moderate hyperplasia and abundant
polymorphonuclear, few lympho-plasmacytic infiltrates beneath the urothelium.
(D) Kidney section of rat inoculated with S. aureus and treated with
Gentamicin (HD) having minimal infiltrates, predominantly lymphocytes
(Gentamicin, LD, 8mg/kg and HD, 50mg/kg).
developing a hybrid drug molecule (here referred as UTIQQ)
to posess better activity was attempted in light of the results
from our previous studies. Initially, GC-MS analysis followed by
computational studies scored the top-hit molecules on applying
the principles of druglikeliness and among the first four top-
hits were found to have sugar moeity and hence exhibited low
druglikeliness. On the other hand, the fifth molecule, although
an acid, has a positive logP and fits into Lipinski’s rule of five
(Lipinski et al., 2012). The molecule bears the chemical name
2-hydroxycinnamic acid, commonly termed as o-coumaric acid
(Table 2). Antioxidant properties have been reported previously
in both o-coumaric acid (Ferguson et al., 2005) and in the more
abundant isomer p-coumaric acid (Elfalleh et al., 2011), which
is found in lignin and as a constituent of pollen honey and
vinegar. O-coumaric acid was found to have interactions with
R84 and R90 (Figure 3). Since the acids qualify rarely as drugs
(accepted only as salts or other derivatives), an attempt was
evoked to hybridize the acid with an earlier established quorum
quencher of SarA, namely the SarABI. The ester between the two
was predicted to have a low binding score of −4.351, but the
ester (UTIQQ) formed between modified form of SarABI and o-
coumaric acid was predicted to have binding sites on R84, R90
and Q64, and a G-score of−5.151 (Figure 4).
The hybrid drug molecule, UTIQQ was then chemically
sysnthesized and validated. Quantitative biofilm assay results by
crystal violet method suggested that the biofilm of S. aureus
clinical isolate (SA13a) and biofilm of mixed species of clinical
isolates of uropathogens got inhibited in the presence of UTIQQ.
This in turn suggest that the interspecies cooperation hinging on
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FIGURE 12 | Histological analyses of kidney tissue sections. (E) Kidney
section of rats inoculated with S. aureus and co-treated with the UTIQQ (LD)
showing minimal dilatation/degeneration of tubules (arrow). The presence of
majority of the tubules in the adjacent areas showed no significant pathological
changes. (F) Kidney section of the rats inoculated with S. aureus and
co-treated with - UTIQQ (HD) revealed moderate lympho-plasmacytic cell
infiltration (arrow). (G) Kidney section of the rat inoculated with S. aureus and
co-treated with the combinatorial drugs, gentamicin and UTIQQ (LD) showed
mild hyperplasia of the urothelium (arrow) and minimal amount of mononuclear
cell infiltrates. (H) Kidney section of the rats inoculated with S. aureus and
co-treated with gentamicin and UTIQQ (HD) having minimal
dilatation/degeneration of tubules with no significant inflammatory changes.
(Gentamicin, LD, 8mg/kg and HD, 50mg/kg; Hybrid molecule UTIQQ, LD,
16mg/kg and HD, 64mg/kg).
S. aureus is instrumental to infections. The co-culture biofilm
results suggests that elimination of S. aureus biofilm leads to
the collapse of the mixed species biofilm as well, caused as
a result of depreciating ecological fitness. Hence, UTIQQ can
potentially be used to treat all UTI infections involving S. aureus,
irrespective of whether it remains the major perpetrator or not.
In addition, no significant difference in the biofilm reduction
was observed between the UTIQQ treated and untreated of sarA
mutant, ALC637 (Figure S2). The result also suggest the mode
of action of the drug on downregulating S.aureus adherence via.,
negatively regulating the quorum regulator, SarA as envisioned
by the docking studies.
The hydrophobicity of the cells were determined by
partitioning the cells between water and xylene, and the measure
of adherence to xylene gave a measure of hydrophobicity of
the cell surface components. The strong biofilm producers were
always highly hydrophobic in nature. In the present study the
strains treated withUTIQQ showed to exhibit less biofilm forming
capabilities with low hydrophobic nature.
CLSM analysis showed mixed populations of UTI pathogens
have been shown to be hit hard by the presence of the
UTIQQ. This is indicative of the suitability of the drug against
UTIs involving S. aureus. Further, the drug, when used in
combination with the broad spectrum antibiotic gentamicin,
resulted increased activity of gentamicin. This implies that the
drug could well be used along with gentamicin at a lower
concentration, and be applied to potentiate antibiotic action as
an additive effect. The mode of action of UTIQQ is that by
destabilizing the biofilm, exposure of cells to external agents
(such as gentamicin in this case) ensues. When the biofilm is
dissipated, the ecosystem of mixed populations fails, in turn
triggering the halt of the infestation. This makes it undemanding
for the antibiotic to penetrate the biofilm and actuate its
bactericidal effects.
In a study involving mice, gestational UTI was identified to
be a cause of miscarriages and premature births (Kaul et al.,
1999). Our in vivo results are in contrast with Kaul et al.
(1999) where they had observed a significant difference in the
percentage mortality of the delivered pups from E. coli infected
mice.We have not observed anymiscarriages or premature births
in the infected rats. However, our quantitative tissue culture
results rules out the possibility of unsuccessful experimental
UTI since the recovery of uropathogenic S. aureus from kidney
samples was achieved (Table 3). In addition, the retainment
of pathogenic virulence in our uropathogen was clearly seen
from the kidney histological sections of the diseased group
showing inflammation (Figure 11). Reduced colony counts and
mild inflammation in the combined treatment of gentamicin
and UTIQQ (Table 3 and Figure 12) suggests again that UTIQQ
could give an addictive effect to gentamicin action like as shown
in our CLSM studies (Figure 10). Overall, the in vitro and
in vivo experimental data suggests that the UTIQQ alone or, in
combination with gentamicin (in our study) could be a possible
therapy for staphylococcal associated UTI.
Conclusions
Urinary tract infections by S. aureus are among the most
difficult-to-treat ailments during pregnancy. This is partly due to
the inability of physicians to prescribe certain broad spectrum
antibiotics, and partly due to the increasingly alarming trend
of pathogens acquiring drug resistance within quick span of
time. Quorum quenching is a neoteric approach to combat
sequelae arising from bacterial infections. Antivirulence drug
therapy aiming to disarm the pathogens is often advantageous
mainly because such drugs work even in resistant strains where
antibacterial or bactericidal drugs fail. Drugs that target the
interbacterial communication are being explored in a bid to stall
the tremendous rate of resistance evolution. Plant constituents
have often had molecules that hinder the growth of bacteria and
this explains why human pathogens do not colonize plants.
In this study, various molecules identified from Melia
dubia has been screened for suitability for being used as
an antagonist against an important transcriptional factor that
regulates virulence and biofilm formation. 2-hydroxycinnamic
acid turned out to be the most probable cause of antibiofilm
activity of M. dubia root ethanolic extracts and hence was
taken up for validation as an ester with 4-benzylamino
cyclohexanol. This concept of hybrid molecule arises when
both the pharmacophores are capable of individual activity,
and enhanced activity when fused into a single pharmacophore
molecule. In vitro studies have established unquestionably the
activity of the drug. Cell culture studies have also demonstrated
the suitability of such a drug on real time in living systems. By
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destabilizing the biofilms involving S. aureus, we can script the
collapse of the ecosystem of the causal mixed species pathogens
and ultimately stall the invasion. A decisive application of
this drug would be to render the pathogens more vulnerable
to antibiotic action and thus eliminate the illness at lower
concentrations of antibiotic, when used in combination with the
quorum blockers.
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Figure S1 | Mean body weight of the delivered pups from gestational UTI
pregnant rats. Differences of the mean body weight of the pups between the
control, diseased and the treated groups were not significant. Gentamicin (LD,
8mg/kg and HD, 50mg/kg); Hybrid molecule UTIQQ (LD, 16mg/kg and HD,
64mg/kg).
Figure S2 | Percentage biofilm inhibition of sarA mutant ALC637
(1sarA::Tn917LTV1) on treatment with UTIQQ by crystal violet method.
Wild-type and sarA mutant strain of S. aureus were UTIQQ treated with a
concentration of 15µg/mL (MBIC50)and 65µg/mL (MBIC90). UTI
QQ treated
cultures were compared with that of untreated S. aureus clinical isolate, SA13
(Negative control). No significant difference in the biofilm reduction was observed
between the treated and untreated sarA mutant, ALC637.
Table S1 | List of ligands obtained fromMelia dubia root extract by GC-MS
analysis.
Table S2 | LDH concentration of untreated Hep-G2 cells and cells treated
with UTIQQ.
Table S3 | MTT assay values of untreated Hep-G2 cells and cells treated
with UTIQQ.
Table S4 | Percentage mortality of pups delivered after the experimental
UTI induced with uropathogenic S. aureus in wistar rats.
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